Generic Name and Formulations:
Hyaluronic acid 20mg/mL; viscoelastic gel for intra-articular inj.
Indications for DUROLANE:
Symptomatic treatment of mild-to-moderate knee or hip osteoarthritis.
Remove joint effusion before inj. Give as a single intra-articular inj. 3mL per knee or hip. Local anesthetic by SC inj or topical freezing agents may be used prior to inj. Use separate syringes for each joint.
Do not inject by intravascular or extra-articular route, or in the synovial tissues or capsule. Avoid infected or severely inflamed synovial joint, active skin disease or infection at or near inj site. Venous or lymphatic stasis in the leg. Pre-existing chondrocalcinosis. Hyaluronic acid sensitivity. Avoid strenuous activity within 48hrs after injection. Pregnancy, nursing mothers: not studied.
Concomitant other intra-articular injectables: not established.
Transient pain, swelling, joint stiffness; infection.
Single-use prefilled syringe (3mL)—1
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Psychological Therapies May Help Older Adults With Chronic Pain
- Traumatic Brain Injury Linked to Increased Parkinson Disease Risk in Veterans
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics